ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
DHEA increases IGF-1 in women but not in men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 7063" data-attributes="member: 3"><p>DHEA has no influence on growth hormone in males but it seems to have an effect in females.</p><p></p><p><a href="http://www.ncbi.nlm.nih.gov/pubmed/17054472#" target="_blank">Clin Endocrinol (Oxf).</a> 2006 Nov;65(5):673-80.</p><p><strong>Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement.</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong></p><p><strong></strong>Abstract</p><p></p><p>OBJECTIVE:</p><p></p><p>GH dose requirement is lower in ACTH replete compared with ACTH deficient hypopituitary patients suggesting that adrenal androgens may augment IGF-I generation for a given GH dose. This study aimed to determine the effect of dehydroepiandrosterone (DHEA) administration on GH dose requirements in hypopituitary adults.</p><p>DESIGN:</p><p></p><p>A double blind placebo controlled trial was conducted adding 50 <a href="http://www.tnvitamins.com/item.php?sourceID=2&utm_source=shopzilla&utm_medium=cpc&utm_content=product&utm_campaign=shopping-comparison&iID=576" target="_blank">mg DHEA</a> to the standard replacement of hypopituitary patients, including GH, over an initial 6 months, followed by an open phase study of 6 months DHEA replacement and a final 2 month washout phase after DHEA withdrawal. The dose of GH was adjusted to achieve a constant serum IGF-I.</p><p>PATIENTS:</p><p></p><p>Thirty female and 21 male hypopituitary patients were enrolled. Data from 26 women and 18 men were analysed after patient withdrawal.</p><p>MEASUREMENTS:</p><p></p><p>The primary outcome objective was the GH dose required to achieve a stable serum IGF-I. Secondary outcome measures were lipoprotein profiles, insulin, insulin sensitivity, IGFBP-3, waist/hip ratio and indices of bone remodelling.</p><p>RESULTS:</p><p></p><p>DHEA replacement in female patients lead to a 14.6 +/- 20% reduction in the dose of GH for a constant serum IGF-I (P < 0.05, 95% CI: 1.8, 32.7). This was maintained for 12 months and there was a significant fall in serum IGF-I two months after withdrawal of DHEA.<u>There was no change in the male group.</u></p><p><u></u></p><p>CONCLUSIONS:</p><p></p><p>DHEA replacement may reduce GH dose requirements in female hypopituitary patients.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 7063, member: 3"] DHEA has no influence on growth hormone in males but it seems to have an effect in females. [URL="http://www.ncbi.nlm.nih.gov/pubmed/17054472#"]Clin Endocrinol (Oxf).[/URL] 2006 Nov;65(5):673-80. [B]Dehydroepiandrosterone (DHEA) replacement reduces growth hormone (GH) dose requirement in female hypopituitary patients on GH replacement. [/B]Abstract OBJECTIVE: GH dose requirement is lower in ACTH replete compared with ACTH deficient hypopituitary patients suggesting that adrenal androgens may augment IGF-I generation for a given GH dose. This study aimed to determine the effect of dehydroepiandrosterone (DHEA) administration on GH dose requirements in hypopituitary adults. DESIGN: A double blind placebo controlled trial was conducted adding 50 [URL="http://www.tnvitamins.com/item.php?sourceID=2&utm_source=shopzilla&utm_medium=cpc&utm_content=product&utm_campaign=shopping-comparison&iID=576"]mg DHEA[/URL] to the standard replacement of hypopituitary patients, including GH, over an initial 6 months, followed by an open phase study of 6 months DHEA replacement and a final 2 month washout phase after DHEA withdrawal. The dose of GH was adjusted to achieve a constant serum IGF-I. PATIENTS: Thirty female and 21 male hypopituitary patients were enrolled. Data from 26 women and 18 men were analysed after patient withdrawal. MEASUREMENTS: The primary outcome objective was the GH dose required to achieve a stable serum IGF-I. Secondary outcome measures were lipoprotein profiles, insulin, insulin sensitivity, IGFBP-3, waist/hip ratio and indices of bone remodelling. RESULTS: DHEA replacement in female patients lead to a 14.6 +/- 20% reduction in the dose of GH for a constant serum IGF-I (P < 0.05, 95% CI: 1.8, 32.7). This was maintained for 12 months and there was a significant fall in serum IGF-I two months after withdrawal of DHEA.[U]There was no change in the male group. [/U] CONCLUSIONS: DHEA replacement may reduce GH dose requirements in female hypopituitary patients. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Thyroid, Pregnenolone, Progesterone, DHEA, etc
Thyroid, DHEA, Pregnenolone, Progesterone, etc
DHEA increases IGF-1 in women but not in men
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top